Pre-surgery treatment for HER2-positive cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a treatment given before surgery for cervical cancer that is both squamous cell type and HER2-positive. It aims to see if this approach works better for patients with these specific markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of cervical squamous cell carcinoma (a common type of cervical cancer).
- Your cancer must be HER2-positive (a protein that can help cancer grow).
- You cannot have cervical adenocarcinoma (another type of cervical cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a HER2-targeted antibody drug (RC48-ADC) given with radiation in people with locally advanced solid tumors that cannot be removed by surgery. It aims to find a safe way to use the treatment and see how well it works in cancers that have HER2 protein on their cells.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.